Login or sign up
For business

Disarm therapeutics

4.0· 12 reviews
Average ratingGreat
4.0/ 5

Based on 12 reviews

533%
433%
333%
20%
10%
Dawson Douglas
Reviews 1

I recently came across a company that is truly dedicated to making a positive impact in the field of neurological disorders. The website is informative and user-friendly, providing valuable insights into their innovative approach. Their commitment to developing treatments that target the underlying causes of neurodegenerative diseases is impressive. The scientific research and partnerships highlighted on the website showcase their dedication to advancing the field. The company's focus on precision medicine gives hope to those affected by these challenging conditions. Overall, my experience with the website left me feeling optimistic about the future of neurology and the potential for groundbreaking therapies.

Patty Paul
Reviews 1

I had a mixed experience with Disarm Therapeutics. The website has a good layout and is easy to navigate. However, I found the customer service to be lacking. It took multiple attempts to get a response to my queries. Overall, I would say they have room for improvement.

Patrick Meares
Reviews 1

Disarm Therapeutics is an average company. Their website disamrtx.com provides basic information about their services. However, they need to improve their communication with customers. The staff is not very responsive and it takes them a long time to address customer inquiries. Overall, the experience with Disarm Therapeutics was just average.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Disarm therapeutics

Lilly unites caring with discovery to create medicines that make life better for people around the world.

Disarm Therapeutics: Revolutionizing the Treatment of Neurological Diseases

Disarm Therapeutics is a biotechnology company that is dedicated to developing innovative therapies for patients suffering from neurological diseases. The company was founded in 2016 by Dr. Alvin Shih, who has over 20 years of experience in drug discovery and development.

The mission of Disarm Therapeutics is to discover and develop breakthrough treatments for patients with neurological diseases by targeting the underlying biology of these conditions. The company's approach is based on cutting-edge research into the molecular mechanisms that drive these diseases, with a focus on identifying new targets for drug development.

One of the key areas of focus for Disarm Therapeutics is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. ALS is a devastating neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately death. There are currently no effective treatments for ALS, making it an area of high unmet medical need.

Disarm Therapeutics has developed a novel approach to treating ALS by targeting a protein called SARM1 (Sterile Alpha And TIR Motif Containing 1). SARM1 plays a critical role in the degeneration of nerve cells in ALS and other neurological diseases, making it an attractive target for drug development.

The company's lead candidate drug, DIS-001, is designed to inhibit SARM1 activity and prevent nerve cell degeneration in patients with ALS. In preclinical studies, DIS-001 has shown promising results in slowing disease progression and improving motor function in animal models of ALS.

In addition to its work on ALS, Disarm Therapeutics is also exploring potential treatments for other neurological diseases such as multiple sclerosis (MS) and peripheral neuropathy. These conditions affect millions of people worldwide and represent significant areas of unmet medical need.

To support its research efforts, Disarm Therapeutics has assembled a world-class team of scientists with expertise in neuroscience, drug discovery, clinical development, and commercialization. The company has also established partnerships with leading academic institutions such as Harvard Medical School and Massachusetts General Hospital to advance its research programs.

Overall, Disarm Therapeutics represents an exciting new player in the field of neurology drug development. With its innovative approach to targeting SARM1-mediated neurodegeneration and its commitment to advancing therapies for patients with neurological diseases worldwide – this biotech firm holds great promise towards revolutionizing treatment options available today!

Categories
Biotechnology